ஜோசபின் லோப்ஸ் கார்டோசோ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜோசபின் லோப்ஸ் கார்டோசோ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜோசபின் லோப்ஸ் கார்டோசோ Today - Breaking & Trending Today

More Support for Gene Assay to Guide Breast Cancer Treatment


email article
Patients with ultralow-risk breast cancer according to genomic assessment had excellent long-term outcomes regardless of clinical risk or whether they received adjuvant therapy, a new analysis of a randomized trial showed.
The 8-year breast cancer-specific survival (BCSS) was 99.2% among patients classified as clinically high-risk but ultralow-risk by the MammaPrint 70-gene assay. Patients with an ultralow-risk genomic assessment and low clinical risk had an 8-year BCSS of 99.7%. Freedom from distant metastasis at 8 years was 97.6% in patients who were clinically and genomically low-risk versus 95.0% for those who were clinically high-risk but genomically low-risk.
In patients with an ultralow-risk genomic assessment, the 8-year distant metastasis-free interval (DMFI) rate was 97.8% with no adjuvant systemic therapy. That compared with an 8-year DMFI of 97.4% in patients who received only adjuvant endocrine therapy and 94.9% in patients who received ....

United States , Noord Holland , Priya Rastogi , Charles Bankhead , Josephine Lopes Cardozo , National Surgical Adjuvant Breast , American Society Of Clinical Oncology , University Of Pittsburgh , Netherlands Cancer Institute , American Society , Clinical Oncology , Surgical Adjuvant Breast , Bowel Project , Medpage Today , Endocrine Therapy , Breast Cancer , ஒன்றுபட்டது மாநிலங்களில் , நூற்த் ஹாலண்ட் , பிரியா ரஸ்டோகி , சார்லஸ் வங்கித் தலை , ஜோசபின் லோப்ஸ் கார்டோசோ , அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் , பல்கலைக்கழகம் ஆஃப் பிட்ஸ்பர்க் , நெதர்லாந்து புற்றுநோய் நிறுவனம் , அமெரிக்கன் சமூகம் , மருத்துவ புற்றுநோயியல் ,